Sidney Smith, MD; Lowell Anthony, MD; L. Jackson Roberts, MD; John A. Oates, MD; Theodore Pincus, MD
Carcinoid tumors are neoplasms of the enterochromaffin cells, the primary clinical manifestations of which include flushing, diarrhea, cardiac valvular lesions, and carcinoid crises with bronchospasm and hypotension (1). The acute symptoms are inhibited by the long-acting octapeptide analog of somatostatin, octreotide (SMS-201-995) (2). Musculoskeletal symptoms have been reported (3) in patients with the carcinoid syndrome, although this problem has not been widely recognized. We describe three patients with the carcinoid syndrome in whom treatment with octreotide was followed by resolution of their musculoskeletal symptoms.
A white woman born in 1920 had metastatic carcinoid tumor noted as an incidental
Smith S, Anthony L, Roberts LJ, Oates JA, Pincus T. Resolution of Musculoskeletal Symptoms in the Carcinoid Syndrome after Treatment with the Somatostatin Analog Octreotide. Ann Intern Med. 1990;112:66–68. doi: 10.7326/0003-4819-112-1-66
Download citation file:
© 2019
Published: Ann Intern Med. 1990;112(1):66-68.
DOI: 10.7326/0003-4819-112-1-66
Hematology/Oncology.
Results provided by: